research DIAGNÓSTICO E MANIFESTAÇÕES PRECOCES NA ASMA PEDIÁTRICA: O QUE SABEMOS?
Recurrent dry cough, wheezing, and respiratory discomfort are key symptoms for diagnosing pediatric asthma.
Search
for
Sort by
Research
870-900 / 1000+ resultsresearch A study of the Geheimratsacken angle as predictor for early diagnosis of androgenetic alopecia in adolescent population
research Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial
Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.
research Genetic variation in the ovine KAP22-1 gene and its effect on wool traits in Egyptian sheep
Certain genetic changes in the KAP22-1 gene are linked to better wool quality in Egyptian sheep.
research Subclinical, early hair regrowth in alopecia areata patients under treatment with baricitinib detected by line‐field confocal optical coherence tomography evaluation
Baricitinib helps with early hair regrowth in people with alopecia areata.
research Alopecia areata
Baricitinib shows promise for severe alopecia areata but isn't a cure and has side effects.
research BPH Medications May Increase Risk of Self-Harm, Depression
BPH medications may increase the risk of self-harm and depression, especially in the first 18 months.
research Recent positive selection of a human androgen receptor/ectodysplasin A2 receptor haplotype and its relationship to male pattern baldness
A specific genetic mutation may increase male pattern baldness risk, especially in Europeans.
research A COMPARISON OF THE TOXICITIES OF 4-(ETHOXYCARBOPHENYL) RETINAMIDE AND SOME OTHER RETINOIDS
4-(Ethoxycarbophenyl) retinamide is much less toxic than other retinoids.
research Aromatase inhibitor–induced hair loss in two adolescents
Two teenage boys lost hair after taking a drug for growth, which was not a known side effect for kids.
research Toxicity Test of Fixed Dose Method on Ethanol Extract of Ramania Leaves (Bouea macrophylla Griffith.) from South Kalimantan
Ramania leaf extract is non-toxic but can cause stomach ulcers at high doses.
research Effectiveness and safety of oral dutasteride for male androgenetic alopecia in real clinical practice: A descriptive monocentric study
Oral dutasteride improves hair growth, reduces hair loss, and is safe for most patients.
research Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
BRAF inhibitors for melanoma often cause skin side effects, but they can be managed with proper care.
research Efficacy of dutasteride on androgenetic alopecia recalcitrant to finasteride
research A rare manifestation of STING-associated vasculopathy with onset in infancy: a case report
Early genetic testing and JAK inhibitors can help treat systemic inflammation in SAVI patients.
research Effects of AiQingHua oil on microcirculation disturbance and alopecia mice model
AiQingHua oil improves blood flow and promotes hair growth in mice.
research An Evaluation of Generic and Disease‐Specific Patient‐Reported Outcome Measures to Assess the Impact of Percentage of Scalp Hair Loss on Health‐Related Quality of Life in a European Population
Disease-specific tools better assess alopecia areata's impact on quality of life.
research Hair
Alopecia areata causes significant emotional and social challenges, especially with more hair loss.
research 314 Molecular genetic dissection of ILVEN leads to successful targeted therapy
Targeted therapy with Ustekinumab significantly improved a skin condition called ILVEN, which is caused by mutations in the CARD14 gene.
research Clinical assessment of CL22209, a standardized proprietary extract of Asparagus racemosus, for mitigating vasomotor and menstrual symptoms in perimenopausal women: A randomized, double-blind, placebo-controlled study
CL22209, an Asparagus racemosus extract, safely reduces perimenopausal symptoms and balances hormones.
research Integrated Safety Analysis of Ritlecitinib in Adolescent Patients with Alopecia Areata from the Randomized, Placebo-Controlled ALLEGRO Phase 2b/3 and Ongoing Open-Label Phase 3 ALLEGRO-LT Studies
research 1108 Comparison of ruxolitinib and a collagen-targeted PTH-based hair cycle stimulant on hair follicle counts and hair growth in the C3H/HeJ engrafted mouse model of alopecia areata
A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.
research Autosomal recessive woolly hair/hypotrichosis with homozygous mutation in the LIPH gene: a case report
A genetic mutation in the LIPH gene causes a rare hair disorder with sparse, curly hair.
research 085 Autoantigen screening in C3H/HeJ mouse model of alopecia areata revealed high antigenicity of melanocyte-associated antigen epitopes
Melanocyte-associated antigens may play a key role in alopecia areata and could be targets for new treatments.
research Changing spectrum of hair and scalp disorders over the last decade in a tertiary medical centre
Hair and scalp disorder visits at a medical center increased over the past decade.
research Evaluation of the rodent Hershberger assay using three reference endocrine disrupters (androgen and antiandrogens)
The assay effectively detects hormonal activity of certain chemicals.
research Treatment of alopecia universalis with oral alitretinoin: A case report
Oral alitretinoin can quickly regrow hair in alopecia universalis.
research Clinical and Molecular Genetic Findings of Cerebral Arteriopathy with Subcortical Infarcts and Leukoencephalopathy
Genetic analysis is crucial for diagnosing and managing cerebral arteriopathy.
research Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study
This study analyzed the post-marketing safety profiles of four JAK inhibitors— tofacitinib, baricitinib, ruxolitinib, and ritlecitinib—used for alopecia areata by examining data from the FDA Adverse Event Reporting System from 2015 to 2025. The results showed that each JAK inhibitor had distinct safety signals: tofacitinib was linked to neuropsychiatric and autoimmune events, baricitinib to thrombocytosis, deep vein thrombosis, and breast cancer, ruxolitinib to pyrexia and elevated blood cholesterol, and ritlecitinib to gastrointestinal events and creatine phosphokinase elevation. The time-to-onset of adverse events varied, with tofacitinib and ruxolitinib showing earlier onset, ritlecitinib clustering within the first month, and baricitinib having a delayed onset. Serious adverse events were mostly related to infections, but varied by agent. The study concludes that JAK inhibitors for alopecia areata have diverse safety profiles, suggesting the need for agent-specific monitoring and personalized risk assessment in clinical settings.
research Analyse de la régulation du gène Hairless et identification des voies de signalisation affectées chez les mutants «bald Mill Hill».
The mutant HR bmh protein affects hair follicle formation by failing to repress vitamin D receptor activity.